Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

2.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
3.

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C.

Mult Scler. 2019 May 8:1352458519845844. doi: 10.1177/1352458519845844. [Epub ahead of print]

PMID:
31066634
4.

Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study.

Cuello JP, Martínez Ginés ML, Kuhle J, García Domínguez JM, Lozano Ros A, Romero Delgado F, Higueras Y, Meldaña Rivera A, Goicochea Briceño H, García-Tizon Larroca S, de-León Ruiz J, Michalak Z, Barro C, Álvarez Lafuente R, Medina Heras S, Fernández Velasco JI, Tejeda-Velarde A, Domínguez-Mozo MI, Muriel A, de Andrés C, Villar LM.

Eur J Neurol. 2019 Apr 12. doi: 10.1111/ene.13965. [Epub ahead of print]

PMID:
30977955
5.

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, Barro C, van Schaik IN, Kuhle J, Eftimov F.

J Peripher Nerv Syst. 2019 Jun;24(2):187-194. doi: 10.1111/jns.12319. Epub 2019 Apr 29.

PMID:
30973667
6.

Predictive Value Positive of MTM Eligibility Criteria under MMA and ACA in Identifying Individuals with Medication Utilization Issues.

Qiao Y, Spivey CA, Wang J, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

J Pharm Health Serv Res. 2018 Dec;9(4):393-401. doi: 10.1111/jphs.12266. Epub 2018 Sep 7.

PMID:
30906425
7.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

8.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

PMID:
30664784
9.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
10.

Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.

Ruberte E, Sinnecker T, Amann M, Gaetano L, Naegelin Y, Penner IK, Kuhle J, Derfuss T, Kappos L, Granziera C, Wuerfel J, Yaldizli Ö.

Eur Neurol. 2018;80(3-4):207-214. doi: 10.1159/000495798. Epub 2019 Jan 3.

PMID:
30605898
11.

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.

Högel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, Airas L.

Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380. [Epub ahead of print]

PMID:
30570436
12.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

13.

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

Mult Scler J Exp Transl Clin. 2018 Dec 6;4(4):2055217318814562. doi: 10.1177/2055217318814562. eCollection 2018 Oct-Dec.

14.

Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury.

Depoorter A, Neumann RP, Barro C, Fisch U, Weber P, Kuhle J, Wellmann S.

Front Neurol. 2018 Nov 20;9:984. doi: 10.3389/fneur.2018.00984. eCollection 2018.

15.

Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study.

Barin L, Kaufmann M, Salmen A, Kamm CP, Gobbi C, Kuhle J, Pot C, Chan A, Czaplinski A, Ajdacic-Gross V, Rodgers S, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

Mult Scler Relat Disord. 2019 Feb;28:17-25. doi: 10.1016/j.msard.2018.11.033. Epub 2018 Dec 2.

PMID:
30530118
16.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
17.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
18.

NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Hayer SN, Krey I, Barro C, Rössler F, Körtvelyessy P, Lemke JR, Kuhle J, Schöls L.

Neurology. 2018 Oct 16;91(16):755-757. doi: 10.1212/WNL.0000000000006357. Epub 2018 Sep 14. No abstract available.

PMID:
30217938
19.

Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke.

Tiedt S, Duering M, Barro C, Kaya AG, Boeck J, Bode FJ, Klein M, Dorn F, Gesierich B, Kellert L, Ertl-Wagner B, Goertler MW, Petzold GC, Kuhle J, Wollenweber FA, Peters N, Dichgans M.

Neurology. 2018 Oct 2;91(14):e1338-e1347. doi: 10.1212/WNL.0000000000006282. Epub 2018 Sep 14.

PMID:
30217937
20.

Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.

Qiao Y, Spivey CA, Wang J, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA.

Inquiry. 2018 Jan-Dec;55:46958018795749. doi: 10.1177/0046958018795749.

21.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
22.

The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research.

Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

BMC Neurol. 2018 Aug 13;18(1):111. doi: 10.1186/s12883-018-1118-0.

23.

The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

Barin L, Salmen A, Disanto G, Babačić H, Calabrese P, Chan A, Kamm CP, Kesselring J, Kuhle J, Gobbi C, Pot C, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).

Mult Scler Relat Disord. 2018 Oct;25:112-121. doi: 10.1016/j.msard.2018.07.013. Epub 2018 Jul 21.

PMID:
30059895
24.

Serum neurofilament light chain is increased in hereditary spastic paraplegias.

Wilke C, Rattay TW, Hengel H, Zimmermann M, Brockmann K, Schöls L, Kuhle J, Schüle R, Synofzik M.

Ann Clin Transl Neurol. 2018 May 21;5(7):876-882. doi: 10.1002/acn3.583. eCollection 2018 Jul.

25.

What are the factors to affect outcome and healing of meniscus bucket handle tears?

Hupperich A, Salzmann GM, Niemeyer P, Feucht M, Eberbach H, Südkamp NP, Kühle J.

Arch Orthop Trauma Surg. 2018 Oct;138(10):1365-1373. doi: 10.1007/s00402-018-2989-7. Epub 2018 Jun 29.

PMID:
29959519
26.

Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden.

Duering M, Konieczny MJ, Tiedt S, Baykara E, Tuladhar AM, Leijsen EV, Lyrer P, Engelter ST, Gesierich B, Achmüller M, Barro C, Adam R, Ewers M, Dichgans M, Kuhle J, de Leeuw FE, Peters N.

J Stroke. 2018 May;20(2):228-238. doi: 10.5853/jos.2017.02565. Epub 2018 May 31.

27.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.

Brain. 2018 Aug 1;141(8):2382-2391. doi: 10.1093/brain/awy154.

PMID:
29860296
28.

A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity.

Puhan MA, Steinemann N, Kamm CP, Müller S, Kuhle J, Kurmann R, Calabrese P, Kesselring J, von Wyl V, Swiss Multiple Sclerosis Registry Smsr.

Swiss Med Wkly. 2018 May 16;148:w14623. doi: 10.4414/smw.2018.14623. eCollection 2018.

29.

Prodromal symptoms of multiple sclerosis in primary care.

Disanto G, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, Simpson A, McDonald L, Rossi A, Benkert P, Kuhle J, Ramagopalan SV, Gobbi C.

Ann Neurol. 2018 Jun;83(6):1162-1173. doi: 10.1002/ana.25247. Epub 2018 May 30.

PMID:
29740872
30.

Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors.

Pinter D, Gattringer T, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Eppinger S, Pirpamer L, Bachmaier G, Ropele S, Wardlaw JM, Kuhle J, Khalil M, Fazekas F.

J Cereb Blood Flow Metab. 2018 May 8:271678X18775215. doi: 10.1177/0271678X18775215. [Epub ahead of print]

PMID:
29737904
31.

Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study.

Wilke C, Bender F, Hayer SN, Brockmann K, Schöls L, Kuhle J, Synofzik M.

J Neurol. 2018 Jul;265(7):1618-1624. doi: 10.1007/s00415-018-8893-9. Epub 2018 May 8.

PMID:
29737427
32.

Neurofilament as Neuronal Injury Blood Marker in Preeclampsia.

Evers KS, Atkinson A, Barro C, Fisch U, Pfister M, Huhn EA, Lapaire O, Kuhle J, Wellmann S.

Hypertension. 2018 Jun;71(6):1178-1184. doi: 10.1161/HYPERTENSIONAHA.117.10314. Epub 2018 Apr 23.

PMID:
29686016
33.

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö.

Mult Scler. 2018 May;24(6):777-785. doi: 10.1177/1352458518768433. Epub 2018 Apr 24.

PMID:
29685071
34.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.

PMID:
29542376
35.

Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.

Spivey CA, Wang J, Qiao Y, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

J Manag Care Spec Pharm. 2018 Feb;24(2):97-107. doi: 10.18553/jmcp.2018.24.2.97.

36.

Serum neurofilament light chain in patients with acute cerebrovascular events.

De Marchis GM, Katan M, Barro C, Fladt J, Traenka C, Seiffge DJ, Hert L, Gensicke H, Disanto G, Sutter R, Peters N, Sarikaya H, Goeggel-Simonetti B, El-Koussy M, Engelter S, Lyrer PA, Christ-Crain M, Arnold M, Kuhle J, Bonati LH.

Eur J Neurol. 2018 Mar;25(3):562-568. doi: 10.1111/ene.13554. Epub 2018 Jan 24.

37.

Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.

Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M.

Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.

PMID:
29212830
38.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

39.

Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV.

Blokhuis C, Doeleman S, Cohen S, Demirkaya N, Scherpbier HJ, Kootstra NA, Kuhle J, Teunissen CE, Verbraak FD, Pajkrt D.

Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5985-5992. doi: 10.1167/iovs.17-22252.

PMID:
29183044
40.

Serum neurofilament light is sensitive to active cerebral small vessel disease.

Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Gröbke S, Voortman M, Pirpamer L, Hofer E, Ropele S, Schmidt R, Kuhle J, Fazekas F, Khalil M.

Neurology. 2017 Nov 14;89(20):2108-2114. doi: 10.1212/WNL.0000000000004645. Epub 2017 Oct 18.

41.

Fluid biomarker and electrophysiological outcome measures for progressive MS trials.

Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J.

Mult Scler. 2017 Oct;23(12):1600-1613. doi: 10.1177/1352458517732844. Review.

PMID:
29041870
42.

Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.

Diebold M, Sievers C, Bantug G, Sanderson N, Kappos L, Kuhle J, Lindberg RLP, Derfuss T.

J Autoimmun. 2018 Jan;86:39-50. doi: 10.1016/j.jaut.2017.09.009. Epub 2017 Sep 27.

PMID:
28958667
43.

Thoracic trauma severity contributes to differences in intensive care therapy and mortality of severely injured patients: analysis based on the TraumaRegister DGU®.

Bayer J, Lefering R, Reinhardt S, Kühle J, Zwingmann J, Südkamp NP, Hammer T; TraumaRegister DGU.

World J Emerg Surg. 2017 Sep 2;12:43. doi: 10.1186/s13017-017-0154-1. eCollection 2017.

44.

[Real-world evidence : Benefits and limitations in multiple sclerosis research].

Ziemssen T, Rothenbacher D, Kuhle J, Berger T.

Nervenarzt. 2017 Oct;88(10):1153-1158. doi: 10.1007/s00115-017-0387-y. Review. German.

PMID:
28776214
45.

Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.

Bischof A, Manigold T, Barro C, Heijnen I, Berger CT, Derfuss T, Kuhle J, Daikeler T.

Ann Rheum Dis. 2018 Jul;77(7):1093-1094. doi: 10.1136/annrheumdis-2017-212045. Epub 2017 Jul 25. No abstract available.

PMID:
28743789
46.

Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.

Rolf L, Muris AH, Mathias A, Du Pasquier R, Koneczny I, Disanto G, Kuhle J, Ramagopalan S, Damoiseaux J, Smolders J, Hupperts R.

Mult Scler. 2018 Sep;24(10):1280-1287. doi: 10.1177/1352458517722646. Epub 2017 Jul 21.

47.

Consensus guidelines for lumbar puncture in patients with neurological diseases.

Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE.

Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007. eCollection 2017.

48.

Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro.

Bridel C, Koel-Simmelink MJA, Peferoen L, Derada Troletti C, Durieux S, Gorter R, Nutma E, Gami P, Iacobaeus E, Brundin L, Kuhle J, Vrenken H, Killestein J, Piersma SR, Pham TV, De Vries HE, Amor S, Jimenez CR, Teunissen CE.

Neuropathol Appl Neurobiol. 2018 Jun;44(4):404-416. doi: 10.1111/nan.12412. Epub 2017 Jun 28.

PMID:
28543098
49.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group.

Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.

50.

Epstein-Barr-negative MS: a true phenomenon?

Dobson R, Kuhle J, Middeldorp J, Giovannoni G.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 3;4(2):e318. doi: 10.1212/NXI.0000000000000318. eCollection 2017 Mar. No abstract available.

Supplemental Content

Support Center